278 results on '"Hsin An Hou"'
Search Results
2. Validation of the prognostic significance of the 2022 European <scp>LeukemiaNet</scp> risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia
- Author
-
Min‐Yen Lo, Xavier Cheng‐Hong Tsai, Chien‐Chin Lin, Feng‐Ming Tien, Yuan‐Yeh Kuo, Wan‐Hsuan Lee, Yen‐Ling Peng, Ming‐Chih Liu, Mei‐Hsuan Tseng, Cheng‐An Hsu, Jui‐Che Chen, Liang‐In Lin, Hsun‐I Sun, Yi‐Kuang Chuang, Bor‐Sheng Ko, Jih‐Luh Tang, Ming Yao, Wen‐Chien Chou, Hsin‐An Hou, and Hwei‐Fang Tien
- Subjects
Hematology - Published
- 2023
3. A three‐gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia
- Author
-
Yu‐Hung Wang, Chi‐Yuan Yao, Chien‐Chin Lin, Kristian Gurashi, Fabio M. R. Amaral, Hasse Bossenbroek, Andres Jerez, Tim C. P. Somervaille, Moritz Binder, Mrinal M. Patnaik, Hsin‐An Hou, Wen‐Chien Chou, Kiran Batta, Daniel H. Wiseman, and Hwei‐Fang Tien
- Subjects
Hematology - Published
- 2023
4. Clinico‐genetic and prognostic analyses of 716 patients with primary <scp>myelodysplastic syndrome</scp> and <scp>myelodysplastic syndrome/acute myeloid leukemia</scp> based on the 2022 International Consensus Classification
- Author
-
Wan‐Hsuan Lee, Chien‐Chin Lin, Cheng‐Hong Tsai, Feng‐Ming Tien, Min‐Yen Lo, Sao‐Chih Ni, Ming Yao, Mei‐Hsuan Tseng, Yuan‐Yeh Kuo, Ming‐Chih Liu, Jih‐Luh Tang, Hsun‐I Sun, Yi‐Kuang Chuang, Wen‐Chien Chou, Hsin‐An Hou, and Hwei‐Fang Tien
- Subjects
Hematology - Published
- 2023
5. Third‐generation sequencing‐selected Scardovia wiggsiae promotes periodontitis progression in mice
- Author
-
Yi‐Wen Chen, Guan‐Hua Wu, Bor‐Shiunn Lee, Chung‐Te Liu, Huei‐Ying Li, Shih‐Jung Cheng, Wei‐Ting Kuo, Jiiang‐Huei Jeng, Po‐Chun Chang, Chun‐Pin Lin, Han‐Yi E. Chou, and Hsin‐Han Hou
- Subjects
Periodontics - Abstract
Periodontitis is an oral-bacteria-directed disease that occurs worldwide. Currently, periodontal pathogens are mostly determined using traditional culture techniques, next-generation sequencing, and microbiological screening system. In addition to the well-known and cultivatable periodontal bacteria, we aimed to discover a novel periodontal pathogen by using DNA sequencing and investigate its role in the progression of periodontitis.This study identified pathogens from subgingival dental plaque in patients with periodontitis by using the Oxford Nanopore Technology (ONT) third-generation sequencing system and validated the impact of selected pathogen in periodontitis progression by ligature-implanted mice.Twenty-five patients with periodontitis and 25 healthy controls were recruited in this study. Subgingival plaque samples were collected for metagenomic analysis. The ONT third-generation sequencing system was used to confirm the dominant bacteria. A mouse model with ligature implantation and bacterial injection verified the pathogenesis of periodontitis. Neutrophil infiltration and osteoclast activity were evaluated using immunohistochemistry and tartrate-resistant acid phosphatase assays in periodontal tissue. Gingival inflammation was evaluated using pro-inflammatory cytokines in gingival crevicular fluids. Alveolar bone destruction in the mice was evaluated using micro-computed tomography and hematoxylin and eosin staining.Scardovia wiggsiae (S. wiggsiae) was dominant in the subgingival plaque of the patients with periodontitis. S. wiggsiae significantly deteriorated ligature-induced neutrophil infiltration, osteoclast activation, alveolar bone destruction, and the secretion of interleukin-6, monocyte chemoattractant protein-1, and tumor necrosis factor-α in the mouse model.Our metagenome results suggested that S. wiggsiae is a dominant flora in patients with periodontitis. In mice, the induction of neutrophil infiltration, proinflammatory cytokine secretion, osteoclast activation, and alveolar bone destruction further verified the pathogenic role of S. wiggsiae in the progress of periodontitis. Future studies investigating the metabolic interactions between S. wiggsiae and other periodontopathic bacteria are warranted.
- Published
- 2022
6. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia
- Author
-
Srdan, Verstovsek, Norio, Komatsu, Harinder, Gill, Jie, Jin, Sung-Eun, Lee, Hsin-An, Hou, Toshiaki, Sato, Albert, Qin, Raymond, Urbanski, Weichung, Shih, Oleh, Zagrijtschuk, Craig, Zimmerman, and Ruben A, Mesa
- Subjects
Cancer Research ,Clinical Trials, Phase III as Topic ,Oncology ,Quinazolines ,Humans ,Hydroxyurea ,Multicenter Studies as Topic ,General Medicine ,Randomized Controlled Trials as Topic ,Thrombocythemia, Essential - Abstract
Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progression of the disease by targeting the molecular source. Hydroxyurea is the recommended treatment, but many patients experience resistance or intolerance. Anagrelide is an approved second-line option for ET, but concerns of a higher frequency of disease transformation may affect its role as a suitable long-term option. Interferons have been evaluated in myeloproliferative neoplasms for over 30 years, but early formulations had safety and tolerability issues. SURPASS-ET (NCT04285086) is a phase III, open-label, multicenter, global, randomized, active-controlled trial that will evaluate the safety, efficacy, tolerability and pharmacokinetics of ropeginterferon alfa-2b compared with anagrelide as second-line therapy in high-risk ET.Essential thrombocythemia (ET) is a condition characterized by having more platelets than normal. The high number of platelets increases the risk of a life-threatening blood clot and/or bleeding. Patients with ET and at a high risk for these events are usually treated first with hydroxyurea (HU), but some patients do not respond properly or may develop significant side effects. Anagrelide is an approved medication used in patients who do not respond to HU. Ropeginterferon alfa-2b is a disease-specific, long-acting interferon with a good safety profile approved in polycythemia vera, another type of myeloproliferative neoplasm. The SURPASS-ET clinical trial will evaluate the safety, efficacy, tolerability and pharmacokinetics of ropeginterferon alfa-2b compared with anagrelide in patients with ET who are resistant or cannot tolerate HU.
- Published
- 2022
7. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
- Author
-
Binay K. Sahoo, Yuh-Charn Lin, Cheng-Fen Tu, Chien-Chin Lin, Wei-Ju Liao, Fu-An Li, Ling-Hui Li, Kurt Yun Mou, Steve R. Roffler, Shu-Ping Wang, Chi-Tai Yeh, Chi-Yuan Yao, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien, and Ruey-Bing Yang
- Subjects
Hematology - Abstract
A hallmark of mixed lineage leukemia gene-rearranged (MLL-r) acute myeloid leukemia that offers an opportunity for targeted therapy is addiction to protein tyrosine kinase signaling. One such signal is the receptor tyrosine kinase Fms-like receptor tyrosine kinase 3 (FLT3) upregulated by cooperation of the transcription factors homeobox A9 (HOXA9) and Meis homeobox 1 (MEIS1). Signal peptide-CUB-EGF-like repeat-containing protein (SCUBE) family proteins have previously been shown to act as a co-receptor for augmenting signaling activity of a receptor tyrosine kinase (e.g., vascular endothelial growth factor receptor). However, whether SCUBE1 is involved in the pathological activation of FLT3 during MLL-r leukemogenesis remains unknown. Here we first show that SCUBE1 is a direct target of HOXA9/MEIS1 that is highly expressed on the MLL-r cell surface and predicts poor prognosis in de novo acute myeloid leukemia. We further demonstrate, by using a conditional knockout mouse model, that Scube1 is required for both the initiation and maintenance of MLL-AF9-induced leukemogenesis in vivo. Further proteomic, molecular and biochemical analyses revealed that the membrane-tethered SCUBE1 binds to the FLT3 ligand and the extracellular ligand-binding domains of FLT3, thus facilitating activation of the signal axis FLT3-LYN (a non-receptor tyrosine kinase) to initiate leukemic growth and survival signals. Importantly, targeting surface SCUBE1 by an anti-SCUBE1 monomethyl auristatin E antibody-drug conjugate led to significantly decreased cell viability specifically in MLL-r leukemia. Our study indicates a novel function of SCUBE1 in leukemia and unravels the molecular mechanism of SCUBE1 in MLL-r acute myeloid leukemia. Thus, SCUBE1 is a potential therapeutic target for treating leukemia caused by MLL rearrangements.
- Published
- 2022
8. Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
- Author
-
Yu‐Hung Wang, Chi‐Yuan Yao, Chien‐Chin Lin, Chi‐Ling Chen, Chia‐Lang Hsu, Cheng‐Hong Tsai, Hsin‐An Hou, Wen‐Chien Chou, and Hwei‐Fang Tien
- Published
- 2022
9. Anti-leukemia effects of Omipalisib in Acute Myeloid Leukemia: inhibition of PI3K-AKT-mTOR signaling and suppression of Mitochondrial Biogenesis
- Author
-
Liang-In Lin, Chi-Yang Tseng, Yu-Hsuan Fu, Da-Liang Ou, Jeng-Wei Lu, and Hsin-An Hou
- Abstract
Omipalisib (GSK2126458), a potent dual PI3K/mTOR inhibitor, is reported to exhibit anti-tumor effect in several kinds of cancers. More than 50% of acute myeloid leukemia (AML) patients display a hyperactivation of PI3K/AKT/mTOR signaling. We investigated the anti-proliferative effect of omipalisib in AML cell lines with varied genetic backgrounds. The OCI-AML3 and THP-1 cell lines had a significant response to omipalisib, with IC50 values of 17.45 nM and 8.93 nM, respectively. We integrated transcriptomic profile and metabolomic analyses, and followed by gene set enrichment analysis (GSEA) and metabolite enrichment analysis. Our findings showed that in addition to inhibiting PI3K/AKT/mTOR signaling and inducing cell cycle arrest at the G0/G1 phase, omipalisib also suppressed mitochondrial respiration and biogenesis. Furthermore, omipalisib downregulated several genes associated with serine, glycine, threonine, and glutathione metabolism, and decreased their protein and glutathione levels. In vivo experiments revealed that omipalisib significantly inhibited tumor growth and prolonged mouse survival without weight loss. Gedatolisib and dactolisib, another two PI3K/mTOR inhibitors, exerted similar effects without affecting mitochondria biogenesis. These results highlight the multifaceted anti-leukemic effect of omipalisib, revealing its potential as a novel therapeutic agent in AML treatment.
- Published
- 2023
10. Data from Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA
- Author
-
Ming-Daw Tsai, Hwei-Fang Tien, Shih-Lan Hsu, Chang-Tze Ricky Yu, Chia-Chi Flora Huang, Hsiang-Chun Su, Ting-Yang Lin, Jo-Mei Maureen Chen, Chih-Ru Lin, Chieh-Lin Jerry Teng, Wen-Chien Chou, Hsin-An Hou, Ting-Jung Wu, Pei-Yu Wu, and Tong-You Wade Wei
- Abstract
Aurora A–dependent NF-κB signaling portends poor prognosis in acute myeloid leukemia (AML) and other cancers, but the functional basis underlying this association is unclear. Here, we report that Aurora A is essential for Thr9 phosphorylation of the TRAF-interacting protein TIFA, triggering activation of the NF-κB survival pathway in AML. TIFA protein was overexpressed concurrently with Aurora A and NF-κB signaling factors in patients with de novo AML relative to healthy individuals and also correlated with poor prognosis. Silencing TIFA in AML lines and primary patient cells decreased leukemic cell growth and chemoresistance via downregulation of prosurvival factors Bcl-2 and Bcl-XL that support NF-κB–dependent antiapoptotic events. Inhibiting TIFA perturbed leukemic cytokine secretion and reduced the IC50 of chemotherapeutic drug treatments in AML cells. Furthermore, in vivo delivery of TIFA-inhibitory fragments potentiated the clearance of myeloblasts in the bone marrow of xenograft-recipient mice via enhanced chemotoxicity. Collectively, our results showed that TIFA supports AML progression and that its targeting can enhance the efficacy of AML treatments. Cancer Res; 77(2); 494–508. ©2016 AACR.
- Published
- 2023
11. Supplementary Data from Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA
- Author
-
Ming-Daw Tsai, Hwei-Fang Tien, Shih-Lan Hsu, Chang-Tze Ricky Yu, Chia-Chi Flora Huang, Hsiang-Chun Su, Ting-Yang Lin, Jo-Mei Maureen Chen, Chih-Ru Lin, Chieh-Lin Jerry Teng, Wen-Chien Chou, Hsin-An Hou, Ting-Jung Wu, Pei-Yu Wu, and Tong-You Wade Wei
- Abstract
Supplementary Methods - construction of plasmids, synthesis of siRNA, and methods for RT-qPCR. Supplementary Figure Legends - legends for supplementary figures. Supplementary References - references for supplementary methods. Supplementary Figures (S1-S7) - S1 shows control experiments for TIFA phosphorylation by Aurora A (A-C), and TIFA interaction with Aurora A (D-E). S2 shows western blot analysis of PBMCs from AML patients and normal donors (A-B), and Pearson's correlation coefficient among TIFA, Aurora A, and NF-κB signaling factors (C). S3 shows that TIFA silencing (A) attenuated cell viabilities (B-C) and enhanced chemotoxicities (D-I) of leukemic lines. S4 shows that TIFA silencing enhanced chemotoxicities of AML PBMCs (A-C) via promotion of apoptosis (D-F). S5 shows that TIFA is a therapeutic target to enhance chemotherapeutic drug treatments. S6 shows that anti-inflammatory drugs enhanced effects of cytarabine treatment in vitro and in vivo (A-B and D), and the control experiments for figure 6D and 6E in the main text (C and E, respectively). S7 shows the schematic model of the functional role of TIFA in supporting leukemic cell growth and chemoresistance. Supplementary Tables (S1-S7) - S1 shows clinical manifestations of AML patients with higher and lower BM TIFA expression. S2 shows comparison of immune phenotypes of leukemia cells between AML patients with higher and lower BM TIFA expression. S3-5 show IC50 values of drugs for AML lines (S3), ALL and CML lines (S4), and AML patient PBMCs (S5) upon silencing of TIFA. S6-7 show IC50 values of drugs for AML
- Published
- 2023
12. Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndromes Defined by International Consensus Classification
- Author
-
Wan-Hsuan Lee, Ming-Tao Tsai, Cheng-Hong Tsai, Feng-Ming Tien, ming-yen lo, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Ming-Chih Liu, Jui-Che Chen, Yi-Tsung Yang, Jih-Luh Tang, Hsun-I Sun, Yi-Kuang Chuang, Liang-In Lin, Wen-Chien Chou, Chien-Chin Lin, Hsin-An Hou, and Hwei-Fang Tien
- Abstract
Myelodysplastic syndromes (MDS) have varied prognoses and require a risk-adapted treatment strategy for treatment optimization. Recently, a molecular prognostic model (Molecular International Prognostic Scoring System [IPSS-M]) that combines clinical parameters, cytogenetic abnormalities, and mutation topography was proposed. This study validated the IPSS-M in 649 patients with primary MDS (based on the 2022 International Consensus Classification [ICC]) and compared its prognostic power to those of the IPSS and revised IPSS (IPSS-R). Overall, 42.5% of the patients were reclassified and 29.3% were up-staged from the IPSS-R. After the reclassification, 16.9% of the patients may receive different treatment strategies. The IPSS-M had greater discriminative potential than the IPSS-R and IPSS. Patients with high, or very high-risk IPSS-M might benefit from allogeneic hematopoietic stem cell transplantation. IPSS-M, age, ferritin level, and the 2022 ICC categorization predicted outcomes independently. After analyzing demographic and genetic features, complementary genetic analyses, including KMT2A-PTD, were suggested for accurate IPSS-M categorization of patients with ASXL1, TET2, STAG2, RUNX1, SF3B1, SRSF2, DNMT3A, U2AF1, and BCOR mutations and those classified as MDS, not otherwise specified with single lineage dysplasia/multi-lineage dysplasia based on the 2022 ICC. This study confirmed that the IPSS-M can better risk-stratified MDS patients for optimized therapeutic decision-making.
- Published
- 2023
13. Deletion of NADPH oxidase 2 attenuates cisplatin-induced acute kidney injury through reducing ROS-induced proximal tubular cell injury and inflammation
- Author
-
Ho-Ching Chen, Hsin-Yu Hou, Junne-Ming Sung, and Chi-Chang Shieh
- Subjects
General Medicine - Abstract
BackgroundsCisplatin is a commonly used chemotherapeutic agent in cancer treatment. However, its high nephrotoxicity limits its therapeutic application and efficacy. Cisplatin induces nephrotoxicity mainly through oxidative stress and inflammation. Reactive oxygen species (ROS) in the kidneys mainly arise from nicotinamide adenine dinucleotide phosphate (NADPH) oxidases 2 (NOX2), which is highly upregulated during ischemia-reperfusion injury and diabetes mellitus. However, its role in cisplatin-induced acute kidney injury (AKI) remains unknown.MethodsA 8-10-week-old NOX2 gene-knockout and wild-type mice were injected with 25 mg/kg cisplatin intraperitoneally for experiments.ResultsWe investigated the role of NOX2 in cisplatin-induced AKI and found that NOX2-mediated ROS production is a key inflammatory mediator of proximal tubular cell injury in cisplatin-induced AKI. NOX2 gene-knockout alleviated cisplatin-induced renal function decline, tubular injury score, kidney injury molecule-1(Kim-1) expression, and interleukin (IL)-6 and IL-1α levels with a reduction of ROS production. Moreover, in cisplatin-induced AKI, intercellular adhesion molecule 1 (ICAM-1) and the chemoattractant CXC ligand 1 (CXCL1) were highly expressed in association with neutrophil infiltration, which were all attenuated by deletion of NOX2.ConclusionThese data indicate that NOX2 aggravates cisplatin nephrotoxicity by promoting ROS-mediated tissue injury and neutrophil infiltration. Thus, appropriate targeting of NOX2/ROS pathway may minimize the risk of cisplatin-induced kidney injury in patients receiving cancer therapy.
- Published
- 2023
14. Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes
- Author
-
Grace A. Ward, Robert P. Dalton, Benjamin S. Meyer, Amy F. McLemore, Amy L. Aldrich, Nghi B. Lam, Alexis H. Onimus, Nicole D. Vincelette, Thu Le Trinh, Xianghong Chen, Alexandra R. Calescibetta, Sean M. Christiansen, Hsin-An Hou, Joseph O. Johnson, Kenneth L. Wright, Eric Padron, Erika A. Eksioglu, and Alan F. List
- Subjects
pyroptosis ,Organic Chemistry ,General Medicine ,MyD88 ,Catalysis ,hematopoiesis ,Computer Science Applications ,Inorganic Chemistry ,TLR9 ,oxidized mitochondrial DNA ,inflammasome ,Toll-like receptor ,Myelodysplastic Syndromes ,DAMP ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy - Abstract
Myelodysplastic Syndromes (MDSs) are bone marrow (BM) failure malignancies characterized by constitutive innate immune activation, including NLRP3 inflammasome driven pyroptotic cell death. We recently reported that the danger-associated molecular pattern (DAMP) oxidized mitochondrial DNA (ox-mtDNA) is diagnostically increased in MDS plasma although the functional consequences remain poorly defined. We hypothesized that ox-mtDNA is released into the cytosol, upon NLRP3 inflammasome pyroptotic lysis, where it propagates and further enhances the inflammatory cell death feed-forward loop onto healthy tissues. This activation can be mediated via ox-mtDNA engagement of Toll-like receptor 9 (TLR9), an endosomal DNA sensing pattern recognition receptor known to prime and activate the inflammasome propagating the IFN-induced inflammatory response in neighboring healthy hematopoietic stem and progenitor cells (HSPCs), which presents a potentially targetable axis for the reduction in inflammasome activation in MDS. We found that extracellular ox-mtDNA activates the TLR9-MyD88-inflammasome pathway, demonstrated by increased lysosome formation, IRF7 translocation, and interferon-stimulated gene (ISG) production. Extracellular ox-mtDNA also induces TLR9 redistribution in MDS HSPCs to the cell surface. The effects on NLRP3 inflammasome activation were validated by blocking TLR9 activation via chemical inhibition and CRISPR knockout, demonstrating that TLR9 was necessary for ox-mtDNA-mediated inflammasome activation. Conversely, lentiviral overexpression of TLR9 sensitized cells to ox-mtDNA. Lastly, inhibiting TLR9 restored hematopoietic colony formation in MDS BM. We conclude that MDS HSPCs are primed for inflammasome activation via ox-mtDNA released by pyroptotic cells. Blocking the TLR9/ox-mtDNA axis may prove to be a novel therapeutic strategy for MDS.
- Published
- 2023
- Full Text
- View/download PDF
15. Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair
- Author
-
Tsung-Chih Chen, Chi-Yuan Yao, Yu-Ren Chen, Chang-Tsu Yuan, Chien-Chin Lin, Yueh-Chwen Hsu, Po-Han Chuang, Chein-Jun Kao, Yi-Hung Li, Hsin-An Hou, Wen-Chien Chou, and Hwei-Fang Tien
- Subjects
Cancer Research ,DNA Repair ,Carcinogenesis ,DNA ,Isocitrate Dehydrogenase ,Repressor Proteins ,Leukemia, Myeloid, Acute ,Mice ,Cell Transformation, Neoplastic ,Mutation ,Genetics ,Animals ,Humans ,Molecular Biology ,Transcription Factors - Abstract
The pathogenesis of acute leukemia involves interaction among genetic alterations. Mutations of IDH1/2 and PHF6 are common and co-exist in some patients of hematopoietic malignancies, but their cooperative effects remain unexplored. In this study, we addressed the question by characterizing the hematopoietic phenotypes of mice harboring neither, Phf6 knockout, Idh2 R172K, or combined mutations. We found that the combined Phf6
- Published
- 2022
16. Clinical outcomes of intravitreal methotrexate injection protocol with a reduced initial frequency for intraocular lymphoma
- Author
-
Hsin-An Hou, Chang-Ping Lin, Chiung-Ju Hsu, Po-Ting Yeh, Wen-Fang Hsu, and Yi-Jui Lee
- Subjects
medicine.medical_specialty ,Medicine (General) ,Visual acuity ,Group B ,Keratitis ,03 medical and health sciences ,0302 clinical medicine ,Punctate keratitis ,R5-920 ,Intravitreal injection ,Intraocular lymphoma ,Statistical significance ,medicine ,Humans ,Retrospective Studies ,business.industry ,Lymphoma, Non-Hodgkin ,Incidence (epidemiology) ,General Medicine ,medicine.disease ,Surgery ,Methotrexate ,030220 oncology & carcinogenesis ,Intravitreal Injections ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,medicine.drug - Abstract
Background/purpose To investigate the clinical characteristics of intraocular lymphoma and to evaluate two protocols of intravitreal methotrexate injection. Methods A retrospective chart review was conducted of newly-diagnosed intraocular lymphoma patients between January 2013 and January 2018 at National Taiwan University Hospital. Patients were divided into two groups. In Group A, intravitreal methotrexate was administered weekly for the initial 8 weeks, every 2 weeks for the following 12 weeks, and then monthly for 7 months. In Group B, intravitreal methotrexate was administered twice a week for the initial 2 weeks, weekly for the subsequent 2 weeks, once every 2 weeks for the next 1 month, and monthly for the last 10 months. Results A total of 12 patients were analyzed in the study; seven of these patients were allocated to Group A. Differences in the overall survival and progression-free survival between the two groups did not yield statistical significance. The median visual acuity was improved from LogMAR 0.46 to LogMAR 0.30 with borderline significance in Group A (p = 0.053). Two of seven patients in Group A and five of five patients in Group B developed punctate keratitis during intravitreal methotrexate injection treatment. Conclusion Intravitreal methotrexate is an effective and repeatable treatment for intraocular lymphoma. A new protocol with reduced frequency of intravitreal injections as shown in this study could potentially produce similar results without a worse prognosis, along with a decrease in the incidence of keratitis.
- Published
- 2022
17. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM):results from an international, double-blind, randomised, controlled, phase 3 study
- Author
-
Srdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N Harrison, Barbara J Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben Mesa, Adi Shacham Abulafia, Bjorn Andreasson, Anna Angona, Rosa Ayala, Soo-Mee Bang, Bruce Bank, Fiorenza Barraco, Eloise Beggiato, Fleur Samantha Benghiat, MassimiliaNo Bonifacio, Claire Bories, Gabriela Borsaru, Mette Brabrand, Andrei Braester, Andes Broliden, Veronika Buxhofer-Ausch, Nathalie Cambier, Marianna Caramella, Benjamin Carpentier, Nicola Cascavilla, Maria Giraldo Castellano, Hung Chang, Chih-Cheng Chen, June-Won Cheong, Yunsuk Choi, Philip Choi, Maria Teresa Corsetti, Isabel Montero Cuadrado, Julia Cunningham, Gandhi Laurent Damaj, Valerio De Stefano, Robert Delage, Regina Garcĺa Delgado, Jose Miguel Torregrosa Diaz, Péter Dombi, Viviane Dubruille, Miklós Egyed, Daniel El Fassi, Anna Elinder-Camburn, Elena Maria Elli, Martin Ellis, Carmen Fava, Salman Fazal, Angela Fleischman, Lynda Foltz, Laura Fox, Nashat Gabrail, Jose Valentĺn Garcĺa-Gutiérrez, Aaron Gerds, Stephane Girault, Heinz Gisslinger, Alexandru Gluvacov, Joachim Göthert, Evgeni (Evgueniy) Hadjiev (Hadzhiev), Kaoutar Hafraoui, Aryan Hamed, Claire Harrison, Hans Hasselbalch, Hanns Hauser, Mark Heaney, Holger Hebart, Jesus Maria Hernandez Rivas, Victor Higuero Saavedra, Christopher Hillis, Hsin-An Hou, Jonathan How, Daniel Huang, Marek Hus, Arpad Illés, Alessandro Isidori, Vadim Ivanov, Peter Johansson, Chul Won Jung, Ilya Kirgner, Maya Koren-Michowitz, Steffen Koschmieder, Szabolcs Ors Kosztolanyi, Natalia Kreiniz, Andrew Kuykendall, Jonathan Lambert, Kamel Laribi, Axelle Lascaux, Noa Lavie, Mihaela Lazaroiu, Michael Leahy, Ewa Lech-Maranda, Won Sik Lee, Ollivier Legrand, Roberto Lemoli, James Liang, Sung-Nam Lim, Michael Loschi, Alessandro Lucchesi, Ioan Macarie, Jean-Pierre Marolleau, Maurizio Martelli, Jiri Mayer, James McCloskey, Christopher McDermott, Brandon McMahon, Priyanka Mehta, Gábor Mikala, Dragana Milojkovic, Philippe Mineur, Elena Mishchenko, Joon Ho Moon, Zsolt Nagy, Srinivasan Narayanan, Casey O'Connell, Stephen Oh, Mario Ojeda-Uribe, Kiat Hoe Ong, Folashade Otegbeye, Jeanne Palmer, Fabrizio Pane, Andrea Patriarca, Giuseppe Pietrantuono, Mark Plander, Uwe Platzbecker, Ritam Prasad, Witold Prejzner, Tobias Rachow, Atanas Radinoff, László Rejtő, Ciro Rinaldi, Tadeusz Robak, Maria Angeles Fernandez Rodriguez, Aaron Ronson, David Ross, Tomasz Sacha, Parvis Sadjadian, Antonio Salar, Guillermo Sanz Santillana, Christof Scheid, Aline Schmidt, Marianne Tang Severinsen, Vera Stoeva, Paweł Szwedyk, Mario Tiribelli, Karolin Trautmann-Grill, Amy Trottier, Nikolay Tzvetkov, Janusz van Droogenbroeck, Alessandro Vannucchi, Nicola Vianelli, Nikolas von Bubnoff, Dominik Wolf, Dariusz Woszczyk, Tomasz Woźny, Tomasz Wróbel, Blanca Xicoy, and Su-Peng Yeh
- Subjects
Anemia/drug therapy ,Treatment Outcome ,Double-Blind Method ,Janus Kinase Inhibitors/therapeutic use ,Danazol/adverse effects ,Humans ,Primary Myelofibrosis/complications ,General Medicine - Abstract
BACKGROUND: Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis.METHODS: MOMENTUM is an international, double-blind, randomised, controlled, phase 3 study that enrolled patients at 107 sites across 21 countries worldwide. Eligible patients were 18 years or older with a confirmed diagnosis of primary myelofibrosis or post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. Patients were randomly assigned (2:1) to receive momelotinib (200 mg orally once per day) plus danazol placebo (ie, the momelotinib group) or danazol (300 mg orally twice per day) plus momelotinib placebo (ie, the danazol group), stratified by total symptom score (TSS; FINDINGS: 195 patients were randomly assigned to either the momelotinib group (130 [67%]) or danazol group (65 [33%]) and received study treatment in the 24-week randomised treatment period between April 24, 2020, and Dec 3, 2021. A significantly greater proportion of patients in the momelotinib group reported a 50% or more reduction in TSS than in the danazol group (32 [25%] of 130 vs six [9%] of 65; proportion difference 16% [95% CI 6-26], p=0·0095). The most frequent grade 3 or higher treatment-emergent adverse events with momelotinib and danazol were haematological abnormalities by laboratory values: anaemia (79 [61%] of 130 vs 49 [75%] of 65) and thrombocytopenia (36 [28%] vs 17 [26%]). The most frequent non-haematological grade 3 or higher treatment-emergent adverse events with momelotinib and danazol were acute kidney injury (four [3%] of 130 vs six [9%] of 65) and pneumonia (three [2%] vs six [9%]).INTERPRETATION: Treatment with momelotinib, compared with danazol, resulted in clinically significant improvements in myelofibrosis-associated symptoms, anaemia measures, and spleen response, with favourable safety. These findings support the future use of momelotinib as an effective treatment in patients with myelofibrosis, especially in those with anaemia.FUNDING: Sierra Oncology.
- Published
- 2023
18. High BM plasma S100A8/A9 is associated with a perturbed microenvironment and poor prognosis in myelodysplastic syndromes
- Author
-
Yu-Hung Wang, Chien-Chin Lin, Chi-Yuan Yao, Fabio Amaral, Shan-Chi Yu, Chein-Jun Kao, Pin-Tsen Shih, Hsin-An Hou, Wen-Chien Chou, and Hwei-Fang Tien
- Subjects
Hematology - Abstract
S100A8/A9 is a proinflammatory protein and plays an essential role in the pathogenesis of myelodysplastic syndromes (MDS) via the S100A8/A9-Toll-like receptors axis. While S100A8/A9 levels have been used as biomarkers in many inflammatory diseases, their clinical relevance has not been conclusively resolved in MDS. To address this, we used an enzyme-linked immunosorbent assay to quantify S100A8/A9 heterodimers in bone marrow (BM) plasma from 215 MDS patients and compared S100A8/A9 levels across patients with various disease risks and genotypes. S100A8/A9 levels correlated with ASXL1 variant allele frequencies significantly. Moreover, mutant ASXL1 with concurrent RUNX1, STAG2, ZRSR2, or EZH2 mutations was associated with higher S100A8/A9 levels. We further showed that higher S100A8/A9 independently predicted inferior leukemia-free survival and overall survival in MDS patients, irrespective of age, Revised International Prognostic Scoring System subgroups, and known detrimental mutations. Lastly, through deep-sequenced transcriptomic analysis, we demonstrated that higher S100A8/A9 in the BM intimated a perturbed microenvironment with enhanced myeloid-derived suppressor cell-mediated tumor immune escape signal, altered metabolism, and impairment in the functions and quantities of CD8+ T cells and NK cells. S100A8/A9 in the BM microenvironment may be a potential biomarker in the prognostication of MDS and target for novel therapy.
- Published
- 2023
19. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML
- Author
-
Xavier Cheng-Hong Tsai, Kuo-Jui Sun, Min-Yen Lo, Feng-Ming Tien, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Yen-Ling Peng, Yi-Kuang Chuang, Bor-Sheng Ko, Jih-Luh Tang, Hsun-I Sun, Ming-Chih Liu, Chia-Wen Liu, Chien-Chin Lin, Ming Yao, Wen-Chien Chou, Hsin-An Hou, and Hwei-Fang Tien
- Subjects
Oncology ,Hematology - Abstract
A set of myelodysplasia-related (MDS-R) gene mutations are incorporated into the 2022 European LeukemiaNet risk classification as adverse genetic factors for acute myeloid leukemia (AML) based on their poor prognostic impact on older patients. The impact of these mutations on younger patients (age de novo non-M3 AML, we identified MDS-R mutations in 32.7% of the total cohort, 44.9% of older patients and 23.4% of younger patients. The patients with MDS-R mutations had a significantly lower complete remission rate in both younger and older age groups. With a median follow-up of 9.2 years, the MDS-R group experienced shorter overall survival (P = 0.034 for older and 0.035 for younger patients) and event-free survival (P = 0.004 for older and 0.042 for younger patients). Furthermore, patients with MDS-R mutations more frequently harbored measurable residual disease that was detectable using next generation sequencing at morphological CR than those without MDS-R mutations. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) might ameliorate the negative impact of MDS-R mutations. In summary, AML patients with MDS-R mutations have significantly poorer outcomes regardless of age. More intensive treatment, such as allo-HSCT and/or novel therapies, is warranted for AML patients with MDS-R mutations.
- Published
- 2023
20. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma
- Author
-
Chieh‐Lung Cheng, Po‐Ting Yeh, Wei‐Quan Fang, Wei‐Li Ma, Hsin‐An Hou, Cheng‐Hong Tsai, Chang‐Ping Lin, and Hwei‐Fang Tien
- Subjects
Cancer Research ,Oncology ,Radiology, Nuclear Medicine and imaging - Abstract
The optimal treatment for vitreoretinal lymphoma (VRL) remains a challenge, as central nervous system (CNS) relapse occurs frequently, leading to the worst impact on survival. We previously proposed combined intravitreal methotrexate and systemic high-dose methotrexate therapy for this disease. This study aimed to report the long-term outcomes of patients with VRL using this combination treatment.We conducted a retrospective cohort study on patients with VRL at a tertiary referral center between 2003 and 2018.Thirty-two patients were included, of whom 23 had primary VRL (PVRL) and nine had concurrent intraocular and CNS diseases. The treatment was well tolerated. Twenty-six (81.3%) patients achieved complete response (CR). After a median follow-up time of 103.5 months, the 5-year survival rate was 73.3%, whereas the 5-year progression-free survival (PFS) rate was 29.9%. Twenty-four (75%) patients relapsed, including 12 with isolated intraocular relapses at first relapse and a total of 17 with CNS/systemic relapses. The development of CNS/systemic relapse negatively affected survival, but intraocular relapse did not. The median CNS/systemic PFS was 69.5 months, but the risk of CNS/systemic relapse increased steadily with a cumulative incidence rate at 2, 5, and 10 years being 22.6%, 44.2%, and 65%, respectively. Multivariate analysis identified concurrent CNS disease at diagnosis as the only poor-risk factor for CNS/systemic relapse.This study confirms good efficacy and acceptable toxicities of the combination approach. However, incorporation of further intensive consolidation strategies into the treatment protocol to effectively prevent subsequent CNS/systemic relapse deserves to be considered.
- Published
- 2022
21. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes
- Author
-
Wan‐Hsuan Lee, Chien‐Chin Lin, Yu‐Hung Wang, Chi‐Yuan Yao, Yuan‐Yeh Kuo, Mei‐Hsuan Tseng, Yen‐Ling Peng, Cheng‐An Hsu, Hsun‐I Sun, Yi‐Kuang Chuang, Chia‐Lang Hsu, Feng‐Ming Tien, Cheng‐Hong Tsai, Wen‐Chien Chou, Hsin‐An Hou, and Hwei‐Fang Tien
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Abstract
Myelodysplastic syndromes (MDS) are a group of clinically and genetically diverse diseases that impose patients with an increased risk of leukemic transformation. While MDS is a disease of the elderly, the interplay between aging and molecular profiles is not fully understood, especially in the Asian population. Thus, we compared the genetic landscape between younger and older patients in a cohort of 698 patients with primary MDS to advance our understanding of the distinct pathogenesis and different survival impacts of gene mutations in MDS according to age. We found that the average mutation number was higher in the older patients than younger ones. The younger patients had more WT1 and CBL mutations, but less mutated ASXL1, DNMT3A, TET2, SF3B1, SRSF2, STAG2, and TP53 than the older patients. In multivariable survival analysis, RUNX1 mutations with higher variant allele frequency (VAF) and U2AF1 and TP53 mutations were independent poor prognostic indicators in the younger patients, whereas DNMT3A and IDH2 mutations with higher VAF and TP53 mutations conferred inferior outcomes in the older patients. In conclusion, we demonstrated the distinct genetic landscape between younger and older patients with MDS and suggested that mutations impact survival in an age-depended manner.
- Published
- 2022
22. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification
- Author
-
Wan-Hsuan, Lee, Chien-Chin, Lin, Cheng-Hong, Tsai, Feng-Ming, Tien, Min-Yen, Lo, Sao-Chih, Ni, Ming, Yao, Mei-Hsuan, Tseng, Yuan-Yeh, Kuo, Ming-Chih, Liu, Jih-Luh, Tang, Hsun-I, Sun, Yi-Kuang, Chuang, Wen-Chien, Chou, Hsin-An, Hou, and Hwei-Fang, Tien
- Abstract
The 2022 International Consensus Classification (ICC) recategorized myeloid neoplasms based on recent advances in the understanding of the biology of hematologic malignancies, in which myelodysplastic syndrome (MDS) with blasts of 10%-19% is classified as MDS/acute myeloid leukemia (AML), MDS with mutated SF3B1, irrespective of the number of ring sideroblasts, as MDS-SF3B1, and those with multi-hit TP53 mutations as MDS with mutated TP53. In the analysis of 716 patients with MDS diagnosed according to the 2016 WHO classification, we found that 75.3% of patients remained in the MDS group based on the ICC, while 24.7% of patients were reclassified to the MDS/AML group after the exclusion of 15 patients who were classified to the AML group. Patients with MDS/AML showed a distinct mutational landscape and had poorer outcomes, compared to those with MDS. In the MDS group, patients with MDS-SF3B1 had higher frequencies of DNMT3A and TET2 mutations than those with MDS, not otherwise specified, with single lineage dysplasia or multilineage dysplasia. Patients with mutated TP53 were associated with dismal outcomes, irrespective of the blast percentage. In conclusion, this study showed that the ICC facilitates efficient segregation and risk-stratification of MDS which can help guide the treatment choice of patients with the disease.
- Published
- 2022
23. The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression
- Author
-
Chi-Yuan Yao, Chien-Chin Lin, Yu-Hung Wang, Chia-Lang Hsu, Chein-Jun Kao, Hsin-An Hou, Wen-Chien Chou, and Hwei-Fang Tien
- Subjects
General Medicine - Abstract
The S100 family proteins are involved in a variety of important biological processes, most notably immune and inflammatory responses. Their dysregulation also plays a role in the pathogenesis of human cancers. S100A4, also known as metastasin, has long been regarded as a biological marker in tumor progression and metastasis in multiple solid cancers, but its clinical significance in acute myeloid leukemia (AML) has not been extensively studied.We retrospectively studied the association between S100A4 gene expression and the clinical characteristics, mutational and transcriptomic profiles of 227 AML patients treated with standard intensive chemotherapy. Genetic mutations of myeloid disease associated genes were analyzed by Sanger sequencing. Microarray-based transcriptomic gene expression profiling was performed on archived bone marrow mononuclear cells. Bioinformatic analyses, including differential gene expression and gene set enrichment analysis, were conducted to delineate the underlying pathogenic mechanisms.Higher S100A4 expression was associated with older age, monocytic differentiation of leukemic cells, and adverse clinical outcome. S100A4 high-expressors had inferior overall survival and disease-free survival; this finding could be validated in the TCGA AML cohort (both the microarray and RNA-seq platforms). Multivariate Cox regression analysis supported S100A4 as an independent prognostic factor. Bioinformatic analysis showed that AML with higher S100A4 expression was enriched for the interferon, NLRP3 inflammasome, and epithelial-mesenchymal transition pathways.This study provides evidence that S100A4 overexpression serves as a poor prognostic biomarker in AML, holds potential to guide treatment planning in the clinic, and indicates novel therapeutic directions.
- Published
- 2022
24. Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
- Author
-
Wen-Chien Chou, Sheng-Chuan Huang, Ming-Chih Liu, Xiu-Wen Liao, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Jia-Hau Liu, Shang-Ju Wu, Hwei-Fang Tien, Chien-Yuan Chen, Hsin-An Hou, Liang-In Lin, Yen-Ling Peng, Szu-Chun Hsu, Bor-Sheng Ko, Ming Yao, Yi-Kuang Chuang, Feng-Ming Tien, Jih-Luh Tang, Chiawen Liu, Mei-Fang Hou, Yu-Sin Wu, and Cheng-Hong Tsai
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,fluids and secretions ,hemic and lymphatic diseases ,Internal medicine ,CEBPA ,medicine ,Humans ,Transplantation ,Chemotherapy ,business.industry ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Cytogenetics ,Myeloid leukemia ,hemic and immune systems ,Hematology ,Prognosis ,Leukemia, Myeloid, Acute ,fms-Like Tyrosine Kinase 3 ,Concomitant ,Mutation ,embryonic structures ,Stem cell ,business ,Nucleophosmin - Abstract
The mutant burden of FLT3-ITD modulates its prognostic impact on patients with acute myeloid leukemia (AML). However, for patients with low allelic ratio (AR) FLT3-ITD (FLT3-ITDlow, AR
- Published
- 2021
25. Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015
- Author
-
Huey-En Tzeng, Li-Nien Chien, Wen-Chien Chou, Hwei-Fang Tien, Hung-Yi Liu, and Hsin-An Hou
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Hazard ratio ,Population ,Subgroup analysis ,Hematology ,General Medicine ,Lower risk ,Confidence interval ,Cancer registry ,Internal medicine ,Propensity score matching ,medicine ,Risk of mortality ,education ,business - Abstract
Since patients with acute myeloid leukemia (AML) in the real world have a much different clinical picture than patients recruited in the clinical trials, obtaining real-world evidence of medication adoption is important for therapeutic efficiency and safety. This study used three population-based data in Taiwan, the National Health Insurance Research Database, Taiwan Cancer Registry, and National Death Registry, between 2001 and 2015, to investigate the effect of conventional chemotherapy (CCT) versus non-conventional chemotherapy (NCCT) on the overall survival (OS) of patients with AML (n = 7,763). Cox proportional hazard regression was used to estimate the hazard ratios (HR) of different treatments on the risk of mortality. To reduce the potential selection bias, we used the inverse probability of treatment weighting based on the propensity score to balance the baseline characteristics between patients receiving CCT and NCCT. The median survival time for CCT and NCCT arms was 10.2 months (95% confidence interval (95% CI): 9.7-10.9) and 4.1 months (95% CI: 3.8-4.5), respectively. Compared to the patients received NCCT, those receiving CCT had a lower risk of mortality (HR 0.63 (95% CI: 0.59-0.67, P
- Published
- 2021
26. Micro-Doppler Shift and Its Estimation in Rotary-Wing UAV Sub-6 GHz Communications
- Author
-
Hsin-An Hou, Li-Chun Wang, and Hsin-Piao Lin
- Subjects
business.industry ,Computer science ,Electrical engineering ,Rotation ,Communications system ,Time–frequency analysis ,Depth sounding ,symbols.namesake ,Control and Systems Engineering ,symbols ,Waveform ,Wireless ,Electrical and Electronic Engineering ,business ,Doppler effect ,Communication channel - Abstract
Rotary-wing unmanned aerial vehicles (UAVs) can be potentially used in wireless communications and therefore attract research from both academia and industry recently. However, most UAV air-to-ground channel models under 6 GHz have ignored the micro-Doppler effects due to the UAV’s propellers. In this letter, we reveal its principle and develop a method to estimate the micro-Doppler, including sounding waveform design, channel modeling, and Doppler frequency estimation. Our simulation results demonstrate that the estimated root-mean-squared error of micro-Doppler is smaller than 18.83 Hz for 963.09 Hz micro-Doppler frequency shift resulting from the rotation of the propellers in the rotary-wing UAV sub-6 GHz communications systems.
- Published
- 2021
27. Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome
- Author
-
Chi-Yuan Yao, Hsin-An Hou, Chia-Lang Hsu, Chien-Chin Lin, Yu-Hung Wang, Wen-Chien Chou, Cheng-Hong Tsai, and Hwei-Fang Tien
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Biopsy ,Bone Marrow Cells ,Kaplan-Meier Estimate ,Gene mutation ,Immunophenotyping ,Pathogenesis ,Immune system ,Bone Marrow ,Internal medicine ,medicine ,Humans ,Aged ,Cluster of differentiation ,business.industry ,Proportional hazards model ,Gene Expression Profiling ,Myelodysplastic syndromes ,High-Throughput Nucleotide Sequencing ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Cell Transformation, Neoplastic ,medicine.anatomical_structure ,International Prognostic Scoring System ,Myelodysplastic Syndromes ,Mutation ,Female ,Disease Susceptibility ,Bone marrow ,business ,Biomarkers - Abstract
Increasing evidence supports the role of the immune microenvironment and associated signalling in the pathogenesis of myelodysplastic syndromes (MDS). Nevertheless, the clinical relevancy of immune signals in patients with MDS remains elusive. To address this, we used single-sample gene-set enrichment analysis to score immune signatures of bone marrow (BM) samples from 176 patients with primary MDS. Enhanced signatures of 'immature dendritic cells' and 'natural killer cells with cluster of differentiation (CD)56bright' were correlated with better overall survival (OS), whilst higher 'CD103+ signature' was associated with reduced survival. An MDS-Immune-Risk (MIR) scoring system was constructed based on the weighted sums derived from Cox regression analysis. High MIR scores were correlated with higher revised International Prognostic Scoring System (IPSS-R) scores and mutations in ASXL transcriptional regulator 1 (ASXL1), Runt-related transcription factor 1 (RUNX1), and tumour protein p53 (TP53). High-score patients had significantly inferior leukaemia-free survival (LFS) and OS than low-score patients. The prognostic significance of MIR scores for survival remained valid across IPSS-R subgroups and was validated in two independent cohorts. Multivariable analysis revealed that a higher MIR score was an independent adverse risk factor for LFS and OS. We further proposed a model with the combination of MIR score and gene mutations to be complementary to IPSS-R for the prognostication of LFS and OS of patients with MDS.
- Published
- 2021
28. PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
- Author
-
Chang-Tsu Yuan, Sze-Hwei Lee, Wen-Chien Chou, Chien-Chin Lin, Hwei-Fang Tien, Jia-Hao Liu, Ko-Ping Chang, Jih-Lu Tang, Chao-Hong Wei, Hsin-An Hou, and Cheng-Hong Tsai
- Subjects
Oncology ,medicine.medical_specialty ,medicine.disease_cause ,B7-H1 Antigen ,Pathology and Forensic Medicine ,Proinflammatory cytokine ,Pathogenesis ,megakaryocyte ,checkpoint ,Megakaryocyte ,Internal medicine ,PD-L1 ,White blood cell ,Pathology ,medicine ,RB1-214 ,Humans ,Myelofibrosis ,Myeloproliferative Disorders ,biology ,business.industry ,Original Articles ,Immune dysregulation ,medicine.disease ,SP142 ,medicine.anatomical_structure ,JAK2 ,PD‐L1 ,Primary Myelofibrosis ,biology.protein ,Immunohistochemistry ,Original Article ,business ,Megakaryocytes - Abstract
Myeloproliferative neoplasms (MPNs) are characterized by upregulation of proinflammatory cytokines and immune dysregulation, which provide a reasonable basis for immunotherapy in patients. Megakaryocytes are crucial in the pathogenesis of primary myelofibrosis (PMF), the most clinically aggressive subtype of MPN. In this study, we aimed to explore PD‐L1 (programmed death‐ligand 1) expression in megakaryocytes and its clinical implications in PMF. We analyzed PD‐L1 expression on megakaryocytes in PMF patients by immunohistochemistry and correlated the results with clinicopathological features and molecular aberrations. We employed a two‐tier grading system considering both the proportion of cells positively stained and the intensity of staining. Among the 85 PMF patients, 41 (48%) showed positive PD‐L1 expression on megakaryocytes with the immune‐reactive score ranging from 1 to 12. PD‐L1 expression correlated closely with higher white blood cell count (p = 0.045), overt myelofibrosis (p = 0.010), JAK2V617F mutation (p = 0.011), and high‐molecular risk mutations (p = 0.045), leading to less favorable overall survival in these patients (hazard ratio 0.341, 95% CI 0.135–0.863, p = 0.023). Our study provides unique insights into the interaction between immunologic and molecular phenotypes in PMF patients. Future work to explore the translational potential of PD‐L1 in the clinical setting is needed.
- Published
- 2021
29. MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
- Author
-
Ruben Mesa, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, and Srdan Verstovsek
- Subjects
Adult ,Aged, 80 and over ,Male ,Cancer Research ,Aspirin ,Interferon-alpha ,Hematology ,Interferon alpha-2 ,Middle Aged ,Recombinant Proteins ,Polyethylene Glycols ,Young Adult ,Treatment Outcome ,Oncology ,Quinazolines ,Humans ,Hydroxyurea ,Female ,Aged ,Thrombocythemia, Essential - Abstract
Low-dose aspirin with hydroxyurea (HU) is first-line therapy in high-risk essential thrombocythemia (ET). However, many patients become HU-intolerant or -resistant. Anagrelide (ANA) and peginterferon alfa-2a are second-line options for high-risk ET patients.To assess the long-term safety and efficacy of P1101 compared to ANA as a second-line option for ET patients with HU intolerance or resistance Design: Phase 3, open-label, multicenter, randomized, active-controlled study to assess the efficacy, safety, tolerability after 12 months of treatment with a 28-day screening and follow-up, for a total trial duration of 14 months. Study visits are scheduled every 2 weeks. Treatments are assigned in a 1:1 ratio and stratified according to baseline platelet count, TSS, and country.Results will impact the treatment of patients with high-risk ET.Subjects diagnosed with high-risk ET (either60 years and JAK2V617F-positive at screening or having thrombosis or hemorrhage in the past) and according to WHO 2016 criteria, documented resistance/intolerance to HU, and IFN naïve are eligible to participate. Key exclusion criteria include pregnant females, autoimmune disease, and history or presence of clinically significant depression.P1101 will be administered subcutaneously every 2 weeks at the starting dose of 250 mcg (Week 0), 350 mcg (Week 2), and target optimal dose of 500 mcg (Week 4) for the remainder of the treatment period. ANA will be dosed according to local country label. All subjects will receive low-dose aspirin unless contraindicated.The primary endpoint is durable modified European LeukemiaNet composite response at 9 and 12 months from start of dosing.The study involves 58 sites across the world. To date 101 patients have been randomized (45 men and 56 women). The mean and median age at recruitment was 58.9 years (SD: 13.4) and 62 years (range 21 to 80 years). 79 subjects had a TSS20. Study is overseen by a DSMB and the need to intervene was not identified.Results will provide the first evidence of a second-line ET treatment by comparing P1101 with the only approved treatment option, ANA. This study is sponsored by PharmaEssentia USA.
- Published
- 2022
30. Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes
- Author
-
Amy F. McLemore, Hsin-An Hou, Benjamin S. Meyer, Nghi B. Lam, Grace A. Ward, Amy L. Aldrich, Matthew A. Rodrigues, Alexis Vedder, Ling Zhang, Eric Padron, Nicole D. Vincelette, David A. Sallman, Omar Abdel-Wahab, Alan F. List, and Kathy L. McGraw
- Subjects
Mice ,Inflammasomes ,Caspases ,Myelodysplastic Syndromes ,Mutation ,NLR Family, Pyrin Domain-Containing 3 Protein ,Animals ,Membrane Proteins ,DNA ,General Medicine ,Nucleotidyltransferases - Abstract
NLRP3 inflammasome and IFN-stimulated gene (ISG) induction are key biological drivers of ineffective hematopoiesis and inflammation in myelodysplastic syndromes (MDSs). Gene mutations involving mRNA splicing and epigenetic regulatory pathways induce inflammasome activation and myeloid lineage skewing in MDSs through undefined mechanisms. Using immortalized murine hematopoietic stem and progenitor cells harboring these somatic gene mutations and primary MDS BM specimens, we showed accumulation of unresolved R-loops and micronuclei with concurrent activation of the cytosolic sensor cyclic GMP-AMP synthase. Cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) signaling caused ISG induction, NLRP3 inflammasome activation, and maturation of the effector protease caspase-1. Deregulation of RNA polymerase III drove cytosolic R-loop generation, which upon inhibition, extinguished ISG and inflammasome response. Mechanistically, caspase-1 degraded the master erythroid transcription factor, GATA binding protein 1, provoking anemia and myeloid lineage bias that was reversed by cGAS inhibition in vitro and in Tet2-/- hematopoietic stem and progenitor cell-transplanted mice. Together, these data identified a mechanism by which functionally distinct mutations converged upon the cGAS/STING/NLRP3 axis in MDS, directing ISG induction, pyroptosis, and myeloid lineage skewing.
- Published
- 2022
31. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
- Author
-
Feng-Ming Tien, Ming-Chih Liu, Mei-Hsuan Tseng, Wen-Chien Chou, Chien-Yu Chen, Ming Yao, Liang-In Lin, Hwei-Fang Tien, Dung-Chi Wu, Yuan-Yeh Kuo, Hsin-An Hou, Chiawen Liu, Cheng-Hong Tsai, Chien-Chin Lin, Yi-Kuang Chuang, Mei-Fang Hou, Yen-Ling Peng, and Jih-Luh Tang
- Subjects
Oncology ,medicine.medical_specialty ,Neoplasm, Residual ,Clinical Trials and Observations ,business.industry ,High-Throughput Nucleotide Sequencing ,Induction chemotherapy ,Consolidation Chemotherapy ,Hematology ,Prognosis ,Minimal residual disease ,Chemotherapy regimen ,body regions ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,Cumulative incidence ,Clinical significance ,Bone marrow ,Time point ,business - Abstract
Next-generation sequencing (NGS) has been applied to measurable/minimal residual disease (MRD) monitoring after induction chemotherapy in patients with acute myeloid leukemia (AML), but the optimal time point for the test remains unclear. In this study, we aimed to investigate the clinical significance of NGS MRD at 2 different time points. We performed targeted NGS of 54 genes in bone marrow cells serially obtained at diagnosis, first complete remission (first time point), and after the first consolidation chemotherapy (second time point) from 335 de novo AML patients. Excluding DNMT3A, TET2, and ASXL1 mutations, which are commonly present in individuals with clonal hematopoiesis of indeterminate potential, MRD could be detected in 46.4% of patients at the first time point (MRD1st), and 28.9% at the second time point (MRD2nd). The patients with detectable NGS MRD at either time point had a significantly higher cumulative incidence of relapse and shorter relapse-free survival and overall survival. In multivariate analysis, MRD1st and MRD2nd were both independent poor prognostic factors. However, the patients with positive MRD1st but negative MRD2nd had a similar good prognosis as those with negative MRD at both time points. The incorporation of multiparameter flow cytometry and NGS MRD revealed that the presence of NGS MRD predicted poorer prognosis among the patients without detectable MRD by multiparameter flow cytometry at the second time point but not the first time point. In conclusion, the presence of NGS MRD, especially after the first consolidation therapy, can help predict the clinical outcome of AML patients.
- Published
- 2021
32. Strategies for Alleviating Tyrosine Kinase Resistance in Acute Myeloid Leukemia By Modulating p53 Signaling Pathway with Small Molecules
- Author
-
Chi-Yang Tseng, Fang-Yu Lo, Yu-Hsuan Fu, Da-Liang Ou, Hsin-An Hou, and Liang-In Lin
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
33. Conditional Knock-out of Phf6 Decreases CD44 Expression on Naïve CD4+ T Cells and Skews the Differentiation Toward Regulatory T Cells in Mice
- Author
-
Tsung-Chih Chen, Chia-Lang Hsu, Chi-Yuan Yao, Yu-Ren Chen, Yueh-Chwen Hsu, Chein-Jun Kao, Hsin-An Hou, Wen-Chien Chou, and Hwei-Fang Tien
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
34. Prognostic Relevance of Adult Acute Myeloid Leukemia Patients According to the 2022 European Leukemianet Risk Stratification
- Author
-
Min Yen Lo, Cheng-Hong Tsai, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Yen-Ling Peng, Cheng-An Hsu, Hsun-I Sun, Yi-Kuang Chuang, Wen-Chien Chou, Hsin-An Hou, and Hwei-Fang Tien
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
35. A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
- Author
-
Yu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, Kristian Gurashi, Fabio Amaral, Andres Jerez, Tim C.P Somervaille, Hsin-An Hou, Wen-Chien Chou, Kiran Batta, Hwei-Fang Tien, and Daniel H Wiseman
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
36. Healthcare Resource Utilization and Costs Associated with AL Amyloidosis: A Retrospective Matched Cohort Study
- Author
-
Hsin-An Hou, Shih-Pei Shen, Kuan-Chih Huang, Choo Hua Goh, Hong Qiu, Lee Anne Rothwell, Kwang-We Wu, Hitesh Chandwani, Yanfang Liu, and Chao-Hsiun Tang
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
37. Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients
- Author
-
Wan‐Hsuan Lee, Chien‐Chin Lin, Cheng‐Hong Tsai, Mei‐Hsuan Tseng, Yuan‐Yeh Kuo, Ming‐Chih Liu, Jih‐Luh Tang, Hsun‐I Sun, Yi‐Kuang Chuang, Wen‐Chien Chou, Hsin‐An Hou, and Hwei‐Fang Tien
- Subjects
Gene Frequency ,Myelodysplastic Syndromes ,Mutation ,Immunology ,Humans ,Cell Biology ,Hematology ,Splicing Factor U2AF ,Prognosis ,Risk Assessment ,Biochemistry - Abstract
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal myeloid malignancies. Though several recurrent mutations are closely correlated with clinical outcomes, data concerning the association between mutation variant allele frequencies (VAF) and prognosis are limited. In this study, we performed comprehensive VAF analyses of relevant myeloid-malignancy related mutations in 698 MDS patients and correlated the results with their prognosis. Mutation VAF in DNMT3A, TET2, ASXL1, EZH2, SETBP1, BCOR, SFSF2, ZRSR2, and TP53 mutations correlated with outcomes. In multivariable analysis, DNMT3A and ZRSR2 mutations with high VAF and mutant IDH2, CBL, U2AF1, and TP53 were independent poor prognostic factors for overall survival. A substantial portion of patients in each revised International Prognostic Scoring System (IPSS-R) risk group could be adjusted to different prognostic groups based on the integrated VAF and mutational profiles. Patients with these unfavorable mutations in each IPSS-R risk subgroup had survivals worse than other patients of the same risk but similar to those in the next higher-risk subgroup. Furthermore, patients harboring U2AF1 mutation might benefit from hypomethylating agents. This study demonstrated the critical role of VAF of mutations for risk stratification in MDS patients and may be incorporated in novel scoring systems.
- Published
- 2022
38. Higher
- Author
-
Yu-Hung, Wang, Chi-Yuan, Yao, Chien-Chin, Lin, Chi-Ling, Chen, Chia-Lang, Hsu, Cheng-Hong, Tsai, Hsin-An, Hou, Wen-Chien, Chou, and Hwei-Fang, Tien
- Published
- 2022
39. Associations of
- Author
-
Chuang-Wei, Wang, Wei-Chen, Lin, Wei-Ti, Chen, Chun-Bing, Chen, Chun-Wei, Lu, Hsin-Han, Hou, Rosaline Chung-Yee, Hui, Jennifer, Wu, Chih-Jung, Chang, Ya-Ching, Chang, and Wen-Hung, Chung
- Abstract
Vancomycin is a commonly used antibiotic; however, it can cause life-threatening severe cutaneous adverse reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS). A previous study has reported a strong association between
- Published
- 2022
40. Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
- Author
-
Courtney D. DiNardo, Pau Montesinos, Lina Benajiba, Ana Triguero, Christian Recher, Andre C. Schuh, Maël Heiblig, Ashish Bajel, Arnaud Pigneux, Juan M. Alonso-Domiguez, Amir T. Fathi, Carolyn Grove, Hsin-An Hou, Michael Heuser, Sarit Assouline, Shaun Fleming, Dong-Yeop Shin, Kendra Sweet, Olatoyosi Odenike, Jessica Altman, Melissa Gaik Ming Ooi, Lao Zhentang, Nobert Vey, Joshua Zeidner, Amandeep Salhotra, Eunice Wang, Gary Schiller, Kimmo Porkka, Tsila Zuckerman, Violaine Havelange, Brian A. Jonas, Sujaatha Narayanan, Jun Ho Jang, Je-Hwan Lee, Anna M. Szpurka, Dana Heirich, Hsiao Rong Chen, Violet Hanft, Junjie Zhao, Ivelina Gueorguieva, Yin Zhang, and Eytan M. Stein
- Subjects
Cancer Research ,Oncology - Abstract
Background: LY3410738 is a potent, selective, covalent, dual inhibitor of IDH1/2 mutations (IDH1/2m). LY3410738 binds covalently at a novel binding site, enabling continued potency in preclinical models in the setting of second site IDH resistance mutations. We present initial results from the first-in-human phase 1 dose escalation study of oral LY3410738 in patients (pts) with R/R IDH1/2m hematologic cancers. Methods: Dose escalation (3+3 design) evaluated LY3410738 monotherapy in IDH1/2m R/R AML (NCT04603001). Key objectives included determining the RP2D, safety, PK, PD (inhibition of plasma D-2-HG), and preliminary antitumor activity. Results: As of 28 July 2022, 114 pts including 108 R/R AML pts received LY3410738 dosed at 5-600 mg QD or 40-300 mg BID. Pts were median 73 years of age (range, 22-92) with a median of 2 prior therapies (range, 1-10); 29% received a prior IDH inhibitor and 58% a prior BCL2 inhibitor. Median time on treatment was 2.3 months (range, 0.1-15). No DLTs or treatment related deaths were observed. Treatment emergent adverse events ≥20% were diarrhea (22%), fatigue (21%), and anemia (20%). Differentiation syndrome was reported in 11 pts (10%); 4 grade 1/2 (4%), 7 grade 3 (6%). LY3410738 exposure was dose proportional. In pts with IDH1m cancers, LY3410738 achieved sustained D-2-HG inhibition at all dose levels including in pts who received prior IDH1 inhibitor. In pts with IDH2m cancers, a higher dose (≥150 mg daily dose) was required for D-2-HG inhibition. Responses were observed in both IDH1m and IDH2m AML (Table). Higher doses were required for IDH2m AML, especially IDH2 R140m pts. Efficacy appears higher in venetoclax naïve pts and limited in IDH inhibitor pre-treated pts. Conclusions: LY3410738 demonstrated a favorable safety profile with potent and sustained D-2-HG inhibition in pts with IDH1m R132, IDH2m R172, and IDH2m R140 mutations. Preliminary efficacy was also seen in all genotypes, in a dose dependent manner. RP2D evaluation is ongoing. Table: Response in R/R AML IDH Inhibitor Naive (N=68) IDH1 R132 IDH2 R172 IDH2 R140 No prior Venetoclax (n=13) Prior Venetoclax (n=19) Total (N=32) Low Dosesa (n=5) (High Dosesb) Total (N=13) Low Dosesa (n=9) (High Dosesb) Total (N=23) No prior Venetoclax (n=3) Prior Venetoclax (n=5) No prior Venetoclax (n=6) Prior Venetoclax (n=8) CR+CRh, n (%) 5 (38%) 2 (11%) 7 (22%) - 3 (100%) 2 (40%) 5 (38%) - 2 (33%) - 2 (9%) CR, n (%) 3 (23%) 2 (11%) 5 (16%) - 2 (67%) 2 (40%) 4 (31%) - 2 (33%) - 2 (9%) CRh, n (%) 2 (15%) - 2 (6%) - 1 (33%) - 1 (8%) - - - - CRc (CR+CRh+CRi/CRp), n (%) 6 (46%) 6 (32%) 12 (38%) - 3 (100%) 3 (60%) 6 (46%) - 2 (33%) - 2 (9%) MFLS, n (%) 1 (8%) 3 (16%) 4 (13%) 2 (40%) - - 2 (15%) 1 (11%) - - 1 (4%) IDH Inhibitor Pre-Treated (N=33) IDH1 R132 IDH2 R172 IDH2 R140 No prior Venetoclax (n=2) Prior Venetoclax (n=8) Total (N=10) Low Dosesa (n=6) (High Dosesb) Total (N=8) Low Dosesa (n=4) (High Dosesb) Total (N=15) No prior Venetoclax (n=1) Prior Venetoclax (n=1) No prior Venetoclax (n=3) Prior Venetoclax (n=8) CR+CRh, n (%) - - - - - - - - - 1 (13%) 1 (7%) CR, n (%) - - - - - - - - - - - CRh, n (%) - - - - - - - - - 1 (13%) 1 (7%) CRc (CR+CRh+CRi/CRp), n (%) - - - - - - - 1 (25%) - 1 (13%) 1 (7%) MLFS, n (%) - - - - - - - - - - - Among the 108 treated R/R AML pts, 101 were efficacy evaluable (42 IDH1 R132, 21 IDH2 R172, 38 IDH2 R140); 68 pts were IDH inhibitor naïve and 33 had received a prior IDH inhibitor treatment. Efficacy evaluable pts are those who had completed the first bone marrow assessment or had discontinued treatment prior to first bone marrow assessment aTotal daily low doses: ≤75 mg Arm A, ≤30 mg Arm B bTotal daily high doses: ≥150 mg Arm A, ≥60 mg Arm B Arm A: not requiring a strong CYP3A4 inhibitor Arm B: requiring a strong CYP3A4 inhibitor Citation Format: Courtney D. DiNardo, Pau Montesinos, Lina Benajiba, Ana Triguero, Christian Recher, Andre C. Schuh, Maël Heiblig, Ashish Bajel, Arnaud Pigneux, Juan M. Alonso-Domiguez, Amir T. Fathi, Carolyn Grove, Hsin-An Hou, Michael Heuser, Sarit Assouline, Shaun Fleming, Dong-Yeop Shin, Kendra Sweet, Olatoyosi Odenike, Jessica Altman, Melissa Gaik Ming Ooi, Lao Zhentang, Nobert Vey, Joshua Zeidner, Amandeep Salhotra, Eunice Wang, Gary Schiller, Kimmo Porkka, Tsila Zuckerman, Violaine Havelange, Brian A. Jonas, Sujaatha Narayanan, Jun Ho Jang, Je-Hwan Lee, Anna M. Szpurka, Dana Heirich, Hsiao Rong Chen, Violet Hanft, Junjie Zhao, Ivelina Gueorguieva, Yin Zhang, Eytan M. Stein. A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT026.
- Published
- 2023
41. Vapor-Induced Pore-Forming Atmospheric-Plasma-Sprayed Zinc-, Strontium-, and Magnesium-Doped Hydroxyapatite Coatings on Titanium Implants Enhance New Bone Formation—An In Vivo and In Vitro Investigation
- Author
-
Hsin-Han Hou, Bor-Shiunn Lee, Yu-Cheng Liu, Yi-Ping Wang, Wei-Ting Kuo, I-Hui Chen, Ai-Chia He, Chern-Hsiung Lai, Kuo-Lun Tung, and Yi-Wen Chen
- Subjects
dental implant ,zinc ,Organic Chemistry ,General Medicine ,magnesium ,Catalysis ,osteogenesis ,Computer Science Applications ,Inorganic Chemistry ,antibacterial ,hydroxyapatite coating ,strontium ,Physical and Theoretical Chemistry ,atmospheric plasma ,Molecular Biology ,Spectroscopy - Abstract
Objectives: Titanium implants are regarded as a promising treatment modality for replacing missing teeth. Osteointegration and antibacterial properties are both desirable characteristics for titanium dental implants. The aim of this study was to create zinc (Zn)-, strontium (Sr)-, and magnesium (Mg)-multidoped hydroxyapatite (HAp) porous coatings, including HAp, Zn-doped HAp, and Zn-Sr-Mg-doped HAp, on titanium discs and implants using the vapor-induced pore-forming atmospheric plasma spraying (VIPF-APS) technique. Methods: The mRNA and protein levels of osteogenesis-associated genes such as collagen type I alpha 1 chain (COL1A1), decorin (DCN), osteoprotegerin (TNFRSF11B), and osteopontin (SPP1) were examined in human embryonic palatal mesenchymal cells. The antibacterial effects against periodontal bacteria, including Porphyromonas gingivalis and Prevotella nigrescens, were investigated. In addition, a rat animal model was used to evaluate new bone formation via histologic examination and micro-computed tomography (CT). Results: The ZnSrMg-HAp group was the most effective at inducing mRNA and protein expression of TNFRSF11B and SPP1 after 7 days of incubation, and TNFRSF11B and DCN after 11 days of incubation. In addition, both the ZnSrMg-HAp and Zn-HAp groups were effective against P. gingivalis and P. nigrescens. Furthermore, according to both in vitro studies and histologic findings, the ZnSrMg-HAp group exhibited the most prominent osteogenesis and concentrated bone growth along implant threads. Significance: A porous ZnSrMg-HAp coating using VIPF-APS could serve as a novel technique for coating titanium implant surfaces and preventing further bacterial infection.
- Published
- 2023
42. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
- Author
-
Hsin-An Hou, Amy L. Aldrich, Amy F McLemore, Susan Geyer, Eric Padron, Kathy L. McGraw, Abhishek Dhawan, Rami S. Komrokji, Sarah Warren, John L. Cleveland, Kyle J. MacBeth, Steffen Boettcher, Alan F. List, Benjamin L. Ebert, Amy Sullivan, Jeffrey E. Lancet, Erika A. Eksioglu, Manja Meggendorfer, Najla Al Ali, Torsten Haferlach, and David A. Sallman
- Subjects
Adult ,Male ,Myeloid ,Immunology ,Gene mutation ,T-Lymphocytes, Regulatory ,Biochemistry ,medicine ,Humans ,Cytotoxic T cell ,RNA, Neoplasm ,Aged ,Aged, 80 and over ,Immunosuppression Therapy ,business.industry ,Myeloid-Derived Suppressor Cells ,Myelodysplastic syndromes ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Phenotype ,Leukemia, Myeloid, Acute ,MicroRNAs ,Haematopoiesis ,Leukemia ,medicine.anatomical_structure ,Myelodysplastic Syndromes ,Mutation ,Cancer research ,Female ,Tumor Suppressor Protein p53 ,Stem cell ,business - Abstract
Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise pathogenetic mechanisms underlying these inferior outcomes have not been delineated. In this study, we characterized the immunological features of the malignant clone and alterations in the immune microenvironment in patients with TP53-mutant and wild-type MDS or sAML. Notably, PDL1 expression is significantly increased in hematopoietic stem cells of patients with TP53 mutations, which is associated with MYC upregulation and marked downregulation of MYC’s negative regulator miR-34a, a p53 transcription target. Notably, patients with TP53 mutations display significantly reduced numbers of bone marrow–infiltrating OX40+ cytotoxic T cells and helper T cells, as well as decreased ICOS+ and 4-1BB+ natural killer cells. Further, highly immunosuppressive regulatory T cells (Tregs) (ie, ICOShigh/PD-1−) and myeloid-derived suppressor cells (PD-1low) are expanded in cases with TP53 mutations. Finally, a higher proportion of bone marrow–infiltrating ICOShigh/PD-1− Treg cells is a highly significant independent predictor of overall survival. We conclude that the microenvironment of TP53 mutant MDS and sAML has an immune-privileged, evasive phenotype that may be a primary driver of poor outcomes and submit that immunomodulatory therapeutic strategies may offer a benefit for this molecularly defined subpopulation.
- Published
- 2020
43. A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan
- Author
-
Hsin-An Hou, Chao-Hsiun Tang, Choo Hua Goh, Shih-Pei Shen, Kuan-Chih Huang, Hong Qiu, Sarah Siggins, Lee Anne Rothwell, and Yanfang Liu
- Subjects
Cohort Studies ,Male ,Multidisciplinary ,Taiwan ,Humans ,Female ,Immunoglobulin Light-chain Amyloidosis ,Amyloidosis ,Middle Aged ,Retrospective Studies - Abstract
The incidence rate of AL (light-chain) amyloidosis is not known in Asia. We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database and Death Registry to estimate incidence and all-cause case fatality rates, and characteristics of patients with AL amyloidosis in Taiwan. All patients with confirmed, newly diagnosed AL amyloidosis from 01-Jan-2016 until 31-Dec-2019 were enrolled and followed up until dis-enrolment, death or study end (31-Dec-2019). There were 841 patients with newly diagnosed AL amyloidosis with median age of 61.4 years and 58.7% were men. At diagnosis, cardiac, renal and liver-related diseases were present in 28.54%, 23.19% and 2.14% of patients, respectively. AL amyloidosis age-adjusted annual incidence was 5.73 per million population in 2016 and 5.26 per million population in 2019. All-cause case fatality ranged from 1.7 to 2.9% over the study period and was highest (~10%) in patients ≥ 80 years. Survival was significantly lower in patients with co-morbid cardiac, renal, or liver-related diseases which could indicate organ involvement. The incidence of AL amyloidosis in Taiwan appears to be similar to Western countries. The poor prognosis in patients with co-morbid diseases highlights the need for earlier diagnosis.
- Published
- 2022
44. Lab-on-PCB: One step away from the accomplishment of
- Author
-
Hsiu-Yang Tseng, Jose H. Lizama, Noel A. S. Alvarado, and Hsin-Han Hou
- Subjects
Fluid Flow and Transfer Processes ,Colloid and Surface Chemistry ,Biomedical Engineering ,General Materials Science ,Condensed Matter Physics ,Perspectives - Abstract
The techniques, protocols, and advancements revolving around printed circuit boards (PCBs) have been gaining sustained attention in the realm of micro-total analysis systems ( μTAS) as more and more efforts are devoted to searching for standardized, highly reliable, and industry-friendly solutions for point-of-care diagnostics. In this Perspective, we set out to identify the current state in which the field of μTAS finds itself, the challenges encountered by researchers in the implementation of these technologies, and the potential improvements that can be targeted to meet the current demands. We also line up some trending innovations, such as 3D printing and wearable devices, along with the development of lab-on-PCB to increase the possibility of multifunctional biosensing activities propelled by integrated microfluidic networks for a wider range of applications, anticipating to catalyze the full potential of μTAS.
- Published
- 2022
45. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria
- Author
-
Asif Siddiqui, Ali T. Taher, Mohamed A. Yassin, Tahir Shamsi, Raymond S.M. Wong, Hsin-An Hou, Junmin Li, Islam Sadek, Soo Jeong Kim, Vikram Mathews, Zhijian Xiao, Tulin Firatli Tuglular, Gerd Rippin, and Wu Depei
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Turkey ,neoplasms ,0302 clinical medicine ,Polycythemia vera ,Bone Marrow ,Epidemiology ,Prevalence ,Prospective Studies ,Registries ,Polycythemia Vera ,Original Research ,Incidence ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,myeloproliferative disorders ,Oncology ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,epidemiology ,Symptom Assessment ,Thrombocythemia, Essential ,medicine.medical_specialty ,Asia ,lcsh:RC254-282 ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Myelofibrosis ,Disease burden ,Aged ,business.industry ,Essential thrombocythemia ,Clinical Cancer Research ,Patient Acceptance of Health Care ,medicine.disease ,Clinical trial ,030104 developmental biology ,quality of life ,Primary Myelofibrosis ,Algeria ,Splenomegaly ,Observational study ,business ,Merge (version control) - Abstract
Philadelphia chromosome‐negative (Ph−) myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders of the bone marrow, and are associated with a high disease burden, reduced quality of life (QOL), and shortened survival. This multinational, multicenter, non‐interventional registry “MERGE” was initiated with an objective to collect data on the epidemiological indices of classical Ph‐MPNs, existing treatment patterns, and impact of MPNs on health‐related QOL in various countries/regions in Asia, including the Middle East, Turkey, and Algeria. Of the 884 eligible patients with MPNs, 169 had myelofibrosis (MF), 301 had polycythemia vera (PV), 373 had essential thrombocythemia (ET), and 41 had unclassified MPNs. The median age was 58 years (range, 47‐66 years), and 50% of patients were males. The prevalence and incidence of MPNs were estimated to be 57‐81 and 12‐15 per 100 000 hospital patients per year over the last 4 years, respectively, in these countries. Total symptom score (mean [standard deviation; SD]) at baseline was highest in patients with MF (23.5 [17.47]) compared with patients with ET (14.6 [14.26]) and PV (16.6 [14.84]). Patients with ET had a lower mean (SD) number of inpatient visits (0.9 [0.77] days), and patients with MF had more outpatient visits (5.2 [3.17] days) on an average, compared with the entire MPN group. The study showed that patients with MPNs have a severe disease burden and reduced QOL. A discordance between physician and patient perception of symptom assessment was observed in this study (International clinical trials registry ID: CTRI/2014/05/004598)., This MERGE registry study provides epidemiological data on the distribution of MPNs and their diagnosis, management, and treatment patterns in developing emerging countries in Asia, including the Middle East, Turkey, and Algeria. The study showed that patients with MPNs have a severe disease burden and reduced quality of life. A discordance between physician and patient perception of symptom assessment was observed in this study.
- Published
- 2020
46. A new species of Pseudobeltrania from leaf spots of Chinese cassia in Taiwan
- Author
-
Roland Kirschner, Ying-Ying Chuang, and Hsin-Yu Hou
- Subjects
Horticulture ,Pseudobeltrania ,biology ,Spots ,Cassia ,Plant Science ,biology.organism_classification ,Ecology, Evolution, Behavior and Systematics - Published
- 2020
47. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients
- Author
-
Hwei-Fang Tien, Chia-Lang Hsu, Chien-Chin Lin, Yu-Hung Wang, Chi-Yuan Yao, Wen-Chien Chou, Cheng-Hong Tsai, and Hsin-An Hou
- Subjects
Oncology ,medicine.medical_specialty ,Subgroup analysis ,LAPTM4B ,Risk Factors ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Risk factor ,Oncogene Proteins ,Myeloid Neoplasia ,business.industry ,Stem Cells ,Membrane Proteins ,Myeloid leukemia ,Hematology ,Prognosis ,medicine.disease ,Leukemia, Myeloid, Acute ,Leukemia ,Haematopoiesis ,International Prognostic Scoring System ,Myelodysplastic Syndromes ,Stem cell ,business - Abstract
Myelodysplastic syndrome (MDS) comprised a heterogeneous group of diseases. The prognosis of patients varies even in the same risk groups. Searching for novel prognostic markers is warranted. Leukemic stem cells (LSCs) are responsible for chemoresistance and relapse in leukemia. Recently, expressions of 17 genes related to stemness of LSCs were found to be associated with prognosis in acute myeloid leukemia patients. However, the clinical impact of LSC genes expressions in MDS, a disorder arising from hematopoietic stem cells, remains unclear. We analyzed expression profile of the 17 stemness-related genes in primary MDS patients and identified expression of 4 genes (LAPTM4B, NGFRAP1, EMP1, and CPXM1) were significantly correlated with overall survival (OS). We constructed an LSC4 scoring system based on the weighted sums of the expression of 4 genes and explored its clinical implications in MDS patients. Higher LSC4 scores were associated with higher revised International Prognostic Scoring System (IPSS-R) scores, complex cytogenetics, and mutations in RUNX1, ASXL1, and TP53. High-score patients had significantly shorter OS and leukemia-free survival (LFS), which was also confirmed in 2 independent validation cohorts. Subgroup analysis revealed the prognostic significance of LSC4 scores for OS remained valid across IPSS-R lower- and higher-risk groups. Furthermore, higher LSC4 score was an independent adverse risk factor for OS and LFS in multivariate analysis. In summary, LSC4 score can independently predict prognosis in MDS patients irrespective of IPSS-R risks and may be used to guide the treatment of MDS patients, especially lower-risk group in whom usually only supportive treatment is given.
- Published
- 2020
48. Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
- Author
-
Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker, Zeidan, A, Ando, K, Rauzy, O, Turgut, M, Wang, M, Cairoli, R, Hou, H, Kwong, Y, Sangerman, M, Meers, S, Pullarkat, V, Santini, V, Malek, K, Kiertsman, F, Lyu, J, Ramos, P, Fenaux, P, Miyazaki, Y, and Platzbecker, U
- Subjects
Sabatolimab, MDS ,MED/15 - MALATTIE DEL SANGUE ,Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
49. Metastasis and Immunosuppression Promoted by MtDNA and PD-L1 in Extracellular Vesicles are Reversed by WGP β-Glucan in Oral Squamous Cell Carcinoma
- Author
-
Shih-Jung Cheng, Hui-Hsin Ko, Hui-Hsin Peng, An Ning Cheng, Han-Yi E. Chou, Hsin-Han Hou, and Alan Yueh-Luen Lee
- Published
- 2022
50. Treatment evolution and improved survival in multiple myeloma in Taiwan
- Author
-
Hong Qiu, Hsin-An Hou, Chao Hsiun Tang, Kuan Chih Huang, and Yanfang Liu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Asia ,Adolescent ,Epidemiology ,Population ,Taiwan ,Disease-Free Survival ,Multiple myeloma ,Internal medicine ,Case fatality rate ,Prevalence ,Humans ,Medicine ,Mortality ,Autografts ,education ,Disease burden ,Aged ,Aged, 80 and over ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Mortality rate ,Hematology ,General Medicine ,Middle Aged ,Survival Rate ,Cohort ,Female ,Original Article ,business ,Follow-Up Studies ,Stem Cell Transplantation ,Cohort study - Abstract
The incidence of multiple myeloma (MM) is increasing worldwide, but the rate of increase is greatest in Asia. Few data describe the epidemiology and treatment of MM in Asia. Building on a cohort study from 2007 to 2012 using the Taiwan National Healthcare Insurance Research database, we extended our analysis to estimate the disease burden and treatment patterns of patients with MM in Taiwan through 2015. A further 1664 patients with newly diagnosed MM from 2013 to 2015 (total 4387 patients from 2007 to 2015) were enrolled and followed up until death or end of the observation period (December 31, 2016), whichever occurred first. The age distribution of the 2013–2015 cohort was similar to that for previous years, but there were fewer men (52.1% versus 58.0%), and more patients had renal impairment at diagnosis (19.7% versus 16.4%). From 2007 to 2015, crude annual incidences per 100,000 population of newly diagnosed MM increased from 1.74 to 2.48 and age-adjusted incidences from 1.41 to 1.65. Crude all-cause mortality rates increased over time. Case fatality decreased from 25.5 to 18.3% and median survival increased from 2.10 to 3.12 years. From 2007 to 2015, the percentage of patients receiving first-line therapy with novel agents increased from 0.4 to 89.4%, autologous stem cell transplantation doubled, and chemotherapy use decreased by 81%. Comprehensive national data covering 9 years of follow-up demonstrate continuing change in the disease burden, treatment, and survival of MM in Taiwan. Despite increased use of new treatments, MM remains largely incurable. Electronic supplementary material The online version of this article (10.1007/s00277-019-03858-w) contains supplementary material, which is available to authorized users.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.